Tags

Type your tag names separated by a space and hit enter

A Single Dose of Viperfav(TM) May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation.
Toxins (Basel). 2016 08 19; 8(8)T

Abstract

Viperfav(TM) is a commercial F(ab')₂ antivenom prepared against European vipers venom. It is safe and effective for treating envenomation caused by Vipera aspis and Vipera berus. Therapeutic efficacy for treating Vipera ammodytes ammodytes (V. a. ammodytes) envenoming has not been yet described, although protective efficacy has been demonstrated in preclinical studies. We report on a 32-year-old man bitten by V. a. ammodytes who was treated with Viperfav™. Viperfav™ promptly reduced local extension and improved systemic pathological signs, but 24 h after the incident a recurrence of thrombocytopenia occurred despite a favorable pharmacokinetic profile with systemic clearance (1.64 (mL·h(-1))·kg(-1)) and elimination half-life (97 h) among the highest ever reported. The recommended dose of Viperfav™ for V. aspis and V. berus bites may be inadequate for serious V. a. ammodytes envenomations. Following V. a. ammodytes bite, serial blood counts and coagulation profiles should be performed to help guide Viperfav™ treatment, along with supplemental administration as indicated.

Authors+Show Affiliations

Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, HR-10000 Zagreb, Croatia. tkurtovi@unizg.hr.Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia. miran.brvar@kclj.si. Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Zaloška cesta 4, 1000 Ljubljana, Slovenia. miran.brvar@kclj.si.Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia. damjan.grenc@kclj.si.Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, HR-10000 Zagreb, Croatia. beata.halassy@unizg.hr.Department of Molecular and Biomedical Sciences, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia. igor.krizaj@ijs.si. Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, 1000 Ljubljana, Slovenia. igor.krizaj@ijs.si.Centre for Research and Knowledge Transfer in Biotechnology, University of Zagreb, Rockefellerova 10, HR-10000 Zagreb, Croatia. maja.langbalija@gmail.com.

Pub Type(s)

Case Reports
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27548220

Citation

Kurtović, Tihana, et al. "A Single Dose of Viperfav(TM) May Be Inadequate for Vipera Ammodytes Snake Bite: a Case Report and Pharmacokinetic Evaluation." Toxins, vol. 8, no. 8, 2016.
Kurtović T, Brvar M, Grenc D, et al. A Single Dose of Viperfav(TM) May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation. Toxins (Basel). 2016;8(8).
Kurtović, T., Brvar, M., Grenc, D., Lang Balija, M., Križaj, I., & Halassy, B. (2016). A Single Dose of Viperfav(TM) May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation. Toxins, 8(8). https://doi.org/10.3390/toxins8080244
Kurtović T, et al. A Single Dose of Viperfav(TM) May Be Inadequate for Vipera Ammodytes Snake Bite: a Case Report and Pharmacokinetic Evaluation. Toxins (Basel). 2016 08 19;8(8) PubMed PMID: 27548220.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Single Dose of Viperfav(TM) May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation. AU - Kurtović,Tihana, AU - Brvar,Miran, AU - Grenc,Damjan, AU - Lang Balija,Maja, AU - Križaj,Igor, AU - Halassy,Beata, Y1 - 2016/08/19/ PY - 2016/06/30/received PY - 2016/08/11/accepted PY - 2016/8/23/entrez PY - 2016/8/23/pubmed PY - 2017/11/9/medline KW - F(ab’)2 antivenom pharmacokinetics KW - Vipera ammodytes ammodytes envenomation KW - Viperfav™ antivenom treatment JF - Toxins JO - Toxins (Basel) VL - 8 IS - 8 N2 - Viperfav(TM) is a commercial F(ab')₂ antivenom prepared against European vipers venom. It is safe and effective for treating envenomation caused by Vipera aspis and Vipera berus. Therapeutic efficacy for treating Vipera ammodytes ammodytes (V. a. ammodytes) envenoming has not been yet described, although protective efficacy has been demonstrated in preclinical studies. We report on a 32-year-old man bitten by V. a. ammodytes who was treated with Viperfav™. Viperfav™ promptly reduced local extension and improved systemic pathological signs, but 24 h after the incident a recurrence of thrombocytopenia occurred despite a favorable pharmacokinetic profile with systemic clearance (1.64 (mL·h(-1))·kg(-1)) and elimination half-life (97 h) among the highest ever reported. The recommended dose of Viperfav™ for V. aspis and V. berus bites may be inadequate for serious V. a. ammodytes envenomations. Following V. a. ammodytes bite, serial blood counts and coagulation profiles should be performed to help guide Viperfav™ treatment, along with supplemental administration as indicated. SN - 2072-6651 UR - https://www.unboundmedicine.com/medline/citation/27548220/A_Single_Dose_of_Viperfav_TM__May_Be_Inadequate_for_Vipera_ammodytes_Snake_Bite:_A_Case_Report_and_Pharmacokinetic_Evaluation_ L2 - https://www.mdpi.com/resolver?pii=toxins8080244 DB - PRIME DP - Unbound Medicine ER -